2008, Number 6
Weekly beta erythropoietin high doses in patients with lymphoblastic acute leukemia in remission and under chemotherapy, its effects in transfusion requirements
PDF size: 109.51 Kb.
ABSTRACTBackground: Eryropoietin has allowed to avoid anemia in patients with neoplasias, and to reduce its transfusion requirements.
Objective: To evaluate if 25,000 UI of recombinant erythropoietin (EPOr) is useful to increase hemoglobin levels (Hb) and to decrease transfusional requirements in patients with acute lymphoblastic leukemia in consolidation and maintenance chemotherapy.
Patients and methods: Prospective study in patients with diagnosis of acute lymphoblastic leukemia, with complete remission, and receiving consolidation and maintenance chemotherapy, during 1 to 6 cycles. Patients were randomized to receive EPOr (25,000 UI once weekly), and transfusional support if Hb decreases less than 8.5 g/dL (EPO group). The other group (NoEPO) recieives transfusional support only if Hb was lower than 8.5 g/dL.
Results: Both groups were similar in age, sex, and chemotherapy and leukemia type. At the end of the study patients receive 96 cycles of chemotherapy: 52 in EPO group and 44 in NoEPO group (p = 0.0005). Hb mean in EPO and No EPO groups was 12.7 g/dL and 10.8 g/dL, respectively (p = 0.001). In EPO group patients received only 2 red cells package and 13 in NoEPO (p = 0.005).
Conclusion: Use of EPOr increase levels of Hb and decrease transfusional requirements, in comparison with the group of patients who don’t receive it.
Rizzo D, Lichtin AE, Woolf SH, Seidenfeld J, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Haematology. Blood 2002;100:2303- 20.
Quesenberry P, Calvin G. Hematopoietic stem cells, progenitor cells, and citokines. Williams Hematology, 6th ed. New York: McGraw-Hill, 2001;pp:153-210.
Florensa L, Coll M, Woessner S. Hematopoyesis: morfología de los elementos formes de la sangre y órganos hematopoyéticos. En: Hematología Clínica. 4a ed. Madrid: Harecourt, 2002;p:35.
Kostova GS. Erythropoietin production in patients with malignant lymphoma. Prilozi 2005;26(2):157-68.
Fujisaka Y, Tamura T, Ohe Y, Kunitoh H, et al. Pharmacokinetics and pharmacodynamics of weekly epoietina beta in lung cancer patients. Jpn J Clin Oncol 2006;36(8):477-82.
Cortesi E, Mancuso A, De Pascale CA, Pizzardi N, et al. Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy. The Oncologist 2004;9:459-68.
Clarke H, Pallister CJ. The impact of anaemia on outcome in cancer. Clin Lab Haem 2005;27:1-13.
González E, López-Hernández MA. Efecto de la eritropoyetina en los niveles de hematócrito y necesidades transfusionales, con globulos rojos, en pacientes con leucemia aguda que reciben quimioterapia de postinduccion. Tesis Recepcional de Hematología. Centro Médico Nacional 20 de Noviembre, ISSSTE, 2007.
Guía para el uso clínico de la sangre. México: Secretaría de Salud, 2007.
Abdelrazik N, Fouda M. Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: A randomized case-controlled study. Hematology 2007; 12(5):1608-15.
Susuki Y, Tokuda Y, Fujiwara Y, Minami H, et al. Weekly epoetin beta maintains hemoglobin levels and improves quality of life in patients with non-myeloid malignancies receiving chemotherapy. Jpn J Clin Oncol 2008;38(3):214-21.
Cullis JO, Duncombe AS, Dudley JM, Lumley HS. Acute leukemia in Jehovah’s Witnesses. Br J Haematology 1998;100(4):664-8.
Bohlius J, Wilson J, Seidenfeld J, Piper M. Erytropoietins andcancer patients: Updated meta-analysis of 57 studies including 9353 patients. Journal of the National Cancer Institute 2006;98(10):708-14.
Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet-Oncol 2003;4(8):459-60.
Leyland JB, Semiglazov V, Pawlicki M, Pienkowski T, et al. Maintaining normal haemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005; 23(25):5960-72.
Brower V. Erythropoietin may impair, not improve, cancer survival. Nat Med 2003;9(12):1439-40.
Takeshita A, Shinjo K, Higuchi M, Miyawaki S, et al. Quantitative expression of erythropoietin receptor (EPO-R) on acute leukaemia cells: relationships between the amount of EPO-R and CD phenotypes, in vitro proliferative response, the amount of other cytokine receptors and clinical prognosis. Japan Adult Leukaemia Study Group. Br J Haematol 2000;108(1):55-63.
Gascon P. Safety Update on erythropoiesis-stimulating agents: trials within and outside the accepted indications. The Oncologist;13(suppl 3):14-10.